{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 33,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/11",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Delayed recall (DPNP)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f32bbf0-8d90-41f0-915c-9221cb0203ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Verbal learning (DPNP)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d19671a0-d62d-437b-ad3f-207ecd8b2444",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "(Phase 2 exploratory endpoints – 180 patients¹)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ee44f76-0ae9-4a19-92a8-799336ce1e4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: * = P < 0.05 vs Placebo; **missed significance (P=0.075); Diabetic Peripheral Neuropathic Pain (DPNP); 1. N=60 patients/treatment group; dosed TID = 3x/day dosing; randomized, cross-over design",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29a5ab09-71bc-4317-aea8-560188a1aef2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "title",
      "text": "RL-007 low doses enhanced learning and memory",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43ddabd6-c4b2-4d88-b521-8273fe45b140",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Additionally, a third-party Phase 2 study in DPNP of RL-007 also showed statistically significant positive cognitive signals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "431043b7-3672-412a-9063-0fb0921164da",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}